IL3RA identified as novel biomarker and therapeutic target for ER+ breast cancer through plasma proteome-wide mendelian randomization and TCGA database analysis
Our study identified IL3RA as novel biomarker and therapeutic target for ER<sup>+</sup> breast cancer. Further validation and mechanistic studies are warranted to advance precision oncology strategies for ER<sup>+</sup> breast cancer management.
Authors
- Nan Jiang (ORCID: https://orcid.org/0000-0001-8394-3247)
- Heting Mei (ORCID: https://orcid.org/0000-0003-0903-2554)
- Zehan Zhang
- Wenping Lu
- Qingya Song
- Feng Li
- Lei Chang
Institutions
- Beijing University of Chinese Medicine (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Guang’anmen Hospital (CN)
- Beijing Hospital of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Clinical Proteomics
- Published
- 2026-03-05
- DOI
- https://doi.org/10.1186/s12014-026-09594-4
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00